The effects of smoking and smoking cessation on nasal mucociliary clearance, mucus properties and inflammation

Daniela Mitiyo Odagiri Utiyama—I, Carolina Tieko Yoshida—I, Danielle Miyuki Goto—I, Tômas de Santana Carvalho—I, Ubiratan de Paula Santos—IV, Andreas Rembert Koczulla—V, Paulo Hilário Nascimento Saldiva—I, Naomi Kondo Nakagawa—I,VI

OBJECTIVE: The aim of the present study was to assess nasal mucociliary clearance, mucus properties and inflammation in smokers and subjects enrolled in a Smoking Cessation Program (referred to as quitters).

METHOD: A total of 33 subjects with a median (IQR) smoking history of 34 (20-58) pack years were examined for nasal mucociliary clearance using a saccharine transit test, mucus properties using contact angle and sneeze clearability tests, and quantification of inflammatory and epithelial cells, IL-6 and IL-8 concentrations in nasal lavage fluid. Twenty quitters (mean age: 51 years, 9 male) were assessed at baseline, 1 month, 3 months and 12 months after smoking cessation, and 13 smokers (mean age: 52 years, 6 male) were assessed at baseline and after 12 months. Clinicaltrials.gov: NCT02136550.

RESULTS: Smokers and quitters showed similar demographic characteristics and morbidities. At baseline, all subjects showed impaired nasal mucociliary clearance (mean 17.6 min), although 63% and 85% of the quitters demonstrated significant nasal mucociliary clearance improvement at 1 month and 12 months, respectively. At 12 months, quitters also showed mucus sneeze clearability improvement (~26%), an increased number of macrophages (2-fold) and no changes in mucus contact angle or cytokine concentrations.

CONCLUSION: This study showed that smoking cessation induced early improvements in nasal mucociliary clearance independent of mucus properties and inflammation. Changes in mucus properties were observed after only 12 months of smoking cessation.

KEYWORDS: Smoking Cessation; Inflammatory Biomarkers; Respiratory Mucus; Exhaled Breath Condensate; Nasal Lavage.

INTRODUCTION

Tobacco smoking is the most relevant, evitable global risk factor for death. Long-term cigarette smoking is associated with numerous structural and functional alterations in the respiratory system. In the nose and upper airways, long-term cigarette smoking affects cilia structure and function (1-3), which can lead to altered mucociliary clearance (MCC) (4-8). MCC is a primary defense mechanism that protects the human airways and lungs against the harmful effects of inhaled particles. Thus, defects in these defense mechanisms contribute to inflammation and obstruction of the small airways (9) and increased susceptibility to respiratory infections (10,11), lung injury, tissue repair problems, chronic dysfunction and progression of respiratory diseases (12,13).

Smoking cessation is an important part of a comprehensive approach to tobacco control (14) and is the best strategy to avoid respiratory risks and complications, to improve chronic obstructive pulmonary disease (COPD) (15) and to reduce cardiovascular risk and mortality (16-18). A few studies have focused on nasal MCC and inflammation and reported improvements after smoking cessation, although...
Mucus properties have not been investigated. The aim of this study was to assess nasal MCC, mucus properties and inflammation at 1, 3 and 12 months after smoking cessation.

MATERIAL AND METHODS

Study population

This study protocol was approved by the Ethical Committee of São Paulo University, São Paulo, Brazil (CEP-FMUSP 235/14) and was conducted in accordance with the Helsinki Declaration (1983). This study is registered at Clinicaltrials.gov (NCT02136550). We recruited subjects (aged above 30 years) from the Ambulatório de Pneumologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, admitted to the Smoking Cessation Program (referred to as quitters). We also recruited smokers from the Faculdade de Medicina da Universidade de São Paulo. The exclusion criteria included the inability to taste saccharine, previous nasal surgery or trauma and infection in the upper and/or lower airways in the 30 days before clinical examination. All participants provided written informed consent.

Study design

The subjects were assessed at the University Laboratory of Pulmonary Defense from 1 P.M. until 6 P.M. Smokers and quitters were assessed at baseline and after 12 months. Quitters were also assessed after 1 and 3 months (Figure 1). For all assessments, subjects were asked to avoid coffee, tea, alcohol and green vegetables at least 12 h prior to analysis. We also asked smokers to refrain from smoking cigarettes at least 2 h prior to measurements. Subjects underwent a physical examination with measurements of arterial blood pressure (mmHg), heart rate (bpm) and pulse oximetry (%) after 10 min of resting.

A current smoker was defined as a subject who had smoked >100 cigarettes and who currently smoked at least one cigarette per day according to the guidelines of the World Health Organization. Subjects enrolled in our Smoking Cessation Program had received a combination of counselling and medication (nicotine replacement therapy, administration of bupropion and/or nortriptyline) for a 3-month period. All subjects enrolled into this study were investigated for concentrations of exhaled carbon monoxide (CO) and cotinine levels in the nasal lavage fluid (NLF). CO was measured using a Micro CO analyzer (Cardinal Health U.K.232 Ltd., Chatham, UK). Subjects were asked to exhale slowly from their total lung capacity with a constant expiratory flow of 5-6 L.min⁻¹ over 10 to 15 sec. Smoking cessation was defined as an exhaled CO <10 ppm and cotinine levels in NLF <10 ng/mL (7).

We also collected demographic data and a clinical history and performed nasal MCC, nasal mucus collection for sneeze clearability and contact angle analysis and NLF collection to measure inflammatory and epithelial cells and cytokine production.

Nasal mucociliary clearance

The subjects were evaluated in standardized conditions of a quiet room with a 21-23°C ambient temperature and 63-71% relative humidity. The subjects remained in a seated position. Briefly, nasal MCC was assessed with the saccharine transit test (STT) (7,19). The STT measures the elapsed time between saccharine deposition 2 cm inside the non-obstructed nostril and the first perception of a sweet taste. We asked subjects to maintain normal ventilation and to avoid deep breaths, coughing, sneezing, sniffing or talking during the test. A normal value for a healthy adult is below 12 min (19).

Mucus collection and analysis

After the STT, we collected nasal mucus with the aid of a soft brush and stored the sample in the freezer (-80°C) for further analysis of mucus sneeze clearability and the mucus contact angle. To evaluate mucus sneeze clearability in vitro, we used a machine that simulates a cough or sneeze;

![Figure 1 - Longitudinal study design.](image-url)
as adapted by King et al. (20). A model acrylic “trachea” cylinder with a cross section of 4 mm and a length of 133 mm was connected to a tank containing pressurized air with a flow of approximately 6 L/s (21). A sample of mucus (25 µl) was deposited in a thin line across the base of the acrylic trachea. Sneeze clearability was measured in millimeters after a single maneuver as the transport distance from the point where the sample was positioned. Wettability refers to the ability to spread over a solid planar surface and is characterized by the contact angle, which is formed between the air-fluid interface and the planar glass. To analyze the contact angle, we used a planar glass pre-treated with a sulphochromic solution and washed with deionized water several times. Five minutes after mucus sample (25 µl) deposition on the planar glass, the measurement of the contact angle was registered using a stereo-microscope (Stemi 2000C, Carl Zeiss, Göttinger, Germany) and to a microcomputer with an image program (Interactive AxionVison 4.7, Carl Zeiss, Göttinger, Germany) (7,19).

Nasal lavage collection
This method has been described previously (7,22). Briefly, subjects were asked to tilt their head back at 30° and to close the nasopharynx with the soft palate. Five milliliters of room temperature isotonic sodium chloride solution (0.9% NaCl) was instilled into each nostril. After 10 sec, the subjects blew the nasopharynx with the soft palate. Five milliliters of room temperature isotonic sodium chloride solution (0.9% NaCl) was instilled into each nostril. After 10 sec, the subjects blew their nose forcefully into a sterile plastic container. The average recovery of fluid from the NLF was approximately 70-75%. The NLF was centrifuged (10 min, 300 g, 5 C) and the supernatant was separated from the pellet and divided into five aliquots of 500 µl. The aliquots were coded (for blinding purposes) and stored at 70-75%. The NLF was centrifuged (10 min, 300 g, 5 C) and the supernatant was separated from the pellet and divided into five aliquots of 500 µl. The aliquots were coded (for blinding purposes) and stored at –80°C for up to 4 weeks to determine the cytokine levels. The cell pellet was used for total and differential cells counts as previously described (7,22).

Total and differential cells counts in the NLF
The cell pellet was resuspended in one milliliter of phosphate-buffered saline solution (7,22). Thereafter, 20 µl of the mixed solution was added to a Neubauer chamber, and the cells were counted using a 400x light microscope (Olympus CH2, Olympus America Inc., Palo Alto, USA). For differential cells count, 100 µl of the mixed solution was centrifuged using a cytopsin (96 g, 25°C, 6 min) to obtain two slides for differential cell counts. The slides were stained according to the May–Grundwald–Giemsa method and analyzed by means of a 1,000x light microscope (Olympus CH2, Olympus America Inc., Palo Alto, USA) by two different observers.

Measurement of cotinine and cytokines in the NLF
To determine the cotinine levels in the NLF, a high-sensitivity saliva cotinine quantitative enzyme immunoassay (DRG International, Inc., USA) was used according to manufacturer’s instructions. The lower detection limit was 0.1 and the standard curve was fitted between 0 and 50 ng/ml [7]. The concentrations of interleukin IL-6 and IL-8 in the NLF were determined using high-sensitivity enzyme immunoassays (Quantikine HS, R&D Systems Inc., Minneapolis, USA). The assays were performed as described by the manufacturer. The reported detection limits were 0.039 pg/ml for IL-6 and 0.11 pg/ml for IL-8, with the standard curve fitted between 0 and 10 pg/ml for IL-6 and 0 and 2,000 pg/ml for IL-8.

Statistical analysis
Data were expressed as the mean ± standard deviation (SD) or median (IQR) when specified. Categorical variables were analyzed by means of the Chi-square test. Analysis of variance (ANOVA) for repeated measures was used to analyze data across the study period with Bonferroni post-hoc tests. Differences were considered statistically significant at a p-value <0.05.

Results
The concentrations of interleukin IL-6 and IL-8 in the NLF were determined using high-sensitivity enzyme immunoassays (Quantikine HS, R&D Systems Inc., Minneapolis, USA). The assays were performed as described by the manufacturer. The reported detection limits were 0.039 pg/ml for IL-6 and 0.11 pg/ml for IL-8, with the standard curve fitted between 0 and 10 pg/ml for IL-6 and 0 and 2,000 pg/ml for IL-8.

Statistical analysis
Data were expressed as the mean ± standard deviation (SD) or median (IQR) when specified. Categorical variables were analyzed by means of the Chi-square test. Analysis of variance (ANOVA) for repeated measures was used to analyze data across the study period with Bonferroni post-hoc tests. Differences were considered statistically significant at a p-value <0.05.

Table 1 - Demographic and clinical characteristics of smokers and quitters at baseline of the study are presented as mean ± SD and analyzed by means of T-test (*) or number (proportion) for categorical variables that were analyzed by means of Chi-Square test.
Smoking Cessation Program, quitters showed a significant decrease in concentrations of exhaled CO that remained low compared with smokers over the observation period of 12 months (Figure 2). Cotinine concentrations in the NLF of quitters decreased after 3 months and remained low after 12 months of smoking cessation.

At baseline, the STT values were prolonged in both groups (Figure 3). After 12 months, smokers showed a similar pattern of impaired nasal MCC. In contrast, quitters showed significant decreases in STT values from 1 month to 12 months. Mucus clearability by sneeze was similar between groups at baseline. The nasal mucus contact angle was similar between the two groups at baseline and did not change during the study period in smokers (33 ± 7° and 35 ± 10°, \( p=0.550 \)) or quitters (36 ± 8° and 32 ± 8°, \( p=0.225 \)).

However, quitters demonstrated improvements in mucus transportability properties after 12 months (Figure 3). At baseline, the total numbers of inflammatory and epithelial cells in the NLF were similar between the two groups. However, smokers showed a higher number of macrophages compared with quitters (Table 2). After 12 months, the quitters showed an increase in the number of macrophages in the NLF (\( p<0.001 \)) with no significant differences between groups. The concentrations of IL-6 and IL-8 were similar between groups at baseline and after 12 months.

**DISCUSSION**

We conducted this 12-month longitudinal study in long-term smokers to investigate the effects of smoking cessation
Smoking cessation readily improves mucus clearance
Utiyama DM et al.

Mucus clearability by high-flow could be associated with restoration of the ionic transport function and mucus hydration at the basolateral membrane (24). However, ciliary beating frequency, cilia structure and epithelium analysis were beyond the scope of this study.

The present study also found that smokers at baseline showed evidence of nasal inflammation, specifically an increased number of inflammatory cells and cytokine levels in NLF. However, in our previous study with young healthy smokers (7), quitters showed a similar number of macrophages (~15 cells) compared to nonsmokers (~14 cells). Thus, we cannot exclude the possibility that quitters in the present study were already reducing their smoking load at the beginning of the study (baseline) or that they could take longer to definitely quit smoking. Additionally, after smoking cessation, there were only small changes in the number of macrophages combined with no changes in pro-inflammatory cytokines (IL-6 and IL-8) in the NLF. However, our results are corroborated by those of others showing maintenance of inflammation in bronchial biopsies of COPD patients (38,39), which can be explained by mechanisms such as airway chronic colonization by viral or bacterial pathogens.

This study has some limitations. First, the sample size of smokers was small and not paired with the quitter group. Indeed, we began with 20 subjects in each group as determined by the sample size calculation. However, seven smokers removed their informed consent after baseline and were excluded from the study. Another limitation was that we may have overestimated the number of subjects who effectively progressed in the smoking cessation program because some subjects may have remained in the quitters group but in fact reinitiated their smoking habit. However, we found it useful to quantify CO in exhaled air and cotinine in the NLF to assess smoking status in the last 2 and 12 hours, respectively, at several time-points of the study and quitters showed a significant decrease in exhaled CO after 1 month of recovery. To highlight differences between the two methods, quitters showed a significant decrease in NLF cotinine levels only after 3 months of recovery. We raise the possibility that this result may be associated with the nicotine replacement therapy delivered during the smoking cessation program. However, we cannot exclude the possibility that subjects may not have adhered to the cessation program after 1 month, taking longer to definitively quit smoking. We did not measure ciliary beat frequency or analyze cilia structure because these methods, such as nasal brushings or biopsies,

### Table 2 - Total number of inflammatory and epithelial cells and cytokine concentrations (pg/mL) in the nasal lavage fluid of smokers and quitters throughout the study. Data are presented as mean values (SD).

|                        | Smokers n=13 | Qitters n=20 |
|------------------------|--------------|-------------|
|                        | Baseline     | 12 months   | Baseline     | 1 month     | 3 months    | 12 months   |
| **Total cells x 10^6** |              |             |              |             |             |             |
| Neutrophils            | 24 (21)      | 44 (37)     | 27 (28)      | 27 (25)     | 33 (29)     | 24 (18)     |
| Lymphocytes            | 9 (7)        | 7 (7)       | 10 (10)      | 11 (9)      | 9 (6)       | 7 (5)       |
| Macrophages            | 33 (14)      | 27 (20)     | 15 (11)*     | 19 (14)     | 17 (11)     | 44 (15)*    |
| Ciliated cells         | 34 (15)      | 21 (17)     | 21 (25)      | 37 (23)     | 22 (22)     | 21 (5)      |
| Goblet cells           | 2 (3)        | 1 (3)       | 10 (14)      | 6 (9)       | 10 (8)      | 3 (3)       |
| **Cytokines**          |              |             |              |             |             |             |
| Interleukin-6          | 2.7 (3.7)    | 3.9 (4.3)   | 2.3 (3.2)    | 3.1 (3.1)   | 2.0 (2.5)   | 2.3 (2.0)   |
| Interleukin-8          | 584.4 (628.9)| 770.4 (518.7)| 415.7 (589.3)| 308.2 (385.4)| 352.9 (275.6)| 472.4 (398.5)|

* p < 0.001 vs. baseline  
† p=0.006 vs. other group at the same period of time
are difficult and more invasive or traumatic to perform in humans. Another limitation was that counting cells with a two-dimensional method does not take into account the volume of the cell. However, we were able to obtain an inflammatory pattern and epithelial cell profile in both groups. Additionally, we are aware that there are studies showing a reduction in MCC with the use of beta-blockers (40) and furosemide (41) via the blockade of water and ionic transport. However, no subject in the present study used furosemide, and only one smoker (8%) used a beta-blocker, which remained the same throughout the study period.

In conclusion, this study showed early improvement in nasal MCC after smoking cessation. Improvements in mucus properties were observed after 12 months of smoking cessation.

Table 3 - A review of mean (± SD) or median (IQR) values for the saccharine transit time in nonsmokers, passive smokers, current smokers and ex-smokers.

| Authors                     | N Subjects | Age (years) | Smoking habit (pack-year) | STT (min) |
|-----------------------------|------------|-------------|---------------------------|-----------|
| Stanley et al. 1986 (3)     | Total n=27 | 33          | Nonsmokers                | 11.1 ± 3.8|
|                             |            |             | Smokers                   | 20.8 ± 9.3*|
| Alfaro-Monge & Soda-Merhy 1995 (33) | Total n=100 |             | Nonsmokers                | 10.3      |
|                             |            |             | Smokers                   | 13.6*     |
| Nakagawa et al. 2005 (5)    | Total n=16 | 32 ± 14     | Nonsmokers                | 10.5      |
|                             |            |             | Smokers                   | 22.0*     |
| Karaman & Tek 2009 (4)      | Nonsmokers n=20 | 18-57      | Nonsmokers                | 12.1 ± 1.9|
|                             | Smokers n=20|             | Smokers > 1               | 26.4 ± 1.8*|
| Piotrowsksa et al. 2010 (32)| Nonsmokers n=21 | 59 ± 9     | Nonsmokers                | 9.9 ± 0.5 |
|                             | COPD n=42   | 50-84       | COPD Smokers: 35.8 ± 13.7 | 16.3 ± 1.6*|
|                             | COPD Smokers n=17 | 61 ± 6  | COPD Ex-smokers           | 11.2 ± 0.5|
| Ramos et al. 2011 (34)      | Nonsmokers n=33 | 52 ± 14    | Nonsmokers                | 8 (7-13)  |
|                             | Smokers n=33 | 49 ± 12     | Smokers: 44 ± 25          | 13 (8-25)*|
| Ito et al. 2015 (35)        | Nonsmokers n=26 | 60 ± 11    | Nonsmokers                | 8 (6-16)  |
|                             | Smokers n=27 | 62 ± 8      | Smokers: 38.8 ± 27.6      | 15.9 (10-27)*|
|                             | COPD Ex-smokers n=23 | 58 ± 8 | COPD Ex-smokers           | 9.7 (6-12) |
|                             | COPD Smokers n=17 | 61 ± 6   | COPD Ex-smokers           | 16.5 (11-28)*|
| Littlejohn et al. 1992 (27) | Total n=10 | > 18        | Smokers                   | 11.7 ± 3.3|
| Mahakit & Pumhirun, 1995 (28)| Total n=40 |             | Nonsmokers                | 12.0      |
|                             |            |             | Smokers                   | 12.4 ± 3.0|
| Proença et al. 2012 (30)    | Nonsmokers n=30 | 49 (44-5) | Nonsmokers                | 8 (8-11)  |
|                             | Smokers n=52 | 50 (42-50)  | Smokers: 62 (36-78)       | 10 (10-13)|
|                             | Light n=17  | 51 (41-54)  | Light: 23 (22-36)        | 9 (7-11)  |
|                             | Moderate n=22 | 47 (38-49)| Moderate: 15 (13-23)     | 13 (11-17)|
|                             | Heavy n=13  | 50 (41-57)  | Heavy: 25 (19-30)       | 13 (10-21)|
| Habesoglu et al. 2012 (29) | Nonsmokers n=15 | 28 ± 11    | Nonsmokers                | 6.4 ± 1.6 |
|                             | Passive smokers n=15 | 29 ± 12  | Passive smokers:          | 12.6 ± 4.7*|
|                             |               |             | < 10 cigarettes/day       | 9.3 ± 4.7 |
|                             |               |             | > 10 cigarettes/day       | 15.5 ± 2.0|
|                             | Active smokers n=17 | 28 ± 11  | Active smokers:           | 23.6 ± 12.4*|
|                             |               |             | < 10 cigarettes/day       | 11.0 ± 3.5|
|                             |               |             | 10-20 cigarettes/day      | 24.3 ± 3.0|
|                             |               |             | > 20 cigarettes/day       | 35.0 ± 14.9|
| Nicola et al. 2014 (7)      | Nonsmokers n=32 | 21 ± 4    | Healthy smokers:          | 7.7 ± 4.1 |
|                             | Smokers n=40  | 19 ± 1      | < 2.5                    | 5.7 ± 2.4*|
|                             |               | 24 ± 5      | Healthy smokers: > 2.5    | 5.9 ± 2.9*|
| Pagliuca et al. 2015 (8)    | Nonsmokers n=30 | 53 ± 6    | Ex-smokers: 25 ± 8        | 11.7      |
|                             | Ex-smokers n=30 | 51 ± 7    | cigarettes/day            | 11.8      |
|                             | Smokers n=3   | 52 ± 6      | Smokers: 25 ± 6 cigarettes/day | 15.6     |
| Utiyama et al. 2016         | Ex-smokers n=20 | 51 ± 9    | Ex-smokers: 40 ± 27       | 8.2 ± 3.1 |
|                             | Smokers n=13  | 52 ± 10     | Smokers: 45 ± 28          | 17.9 ± 10.1*|

* p < 0.05 vs. nonsmokers

ACKNOWLEDGMENTS

We would like to thank Fundação de Amparo à Pesquisa do Estado de São Paulo for financial support (FAPESP 2013/13598-1).

AUTHOR CONTRIBUTIONS

Utiyama DM, Goto DM and Santos UP performed the literature search, conception and design, acquisition of data, analysis of data and interpretation of data. Yoshida CT performed the literature search, analysis of data and interpretation of data. Nakagawa NK performed the literature search, conception and design, analysis of data and interpretation of data. Saldiva PH contributed to the study conception and design. Utiyama DM, Goto DM, Yoshida CT, Carvalho TS, Santos UP, Koczulla AR, Saldiva PH and Nakagawa NK drafted or revised the article and provided final approval of the manuscript.
REFERENCES

1. Verra F, Escudier E, Lebargy F, Bernaudin JF, Crémuoux H, Bignon J. Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and non-smokers. Am J Respir Cell Mol Biol. 1995;13(3 Pt 1):630-4. http://dx.doi.org/10.1164/ajrcmb.1995.13.3-1.630.

2. Leopold PL, O'Mahony MJ, Lian XJ, Tilley AE, Harvey BC, Crystal RG. Smoking is associated with shortened airway cilia. PLoS One. 2009;4(12):1-11, http://dx.doi.org/10.1371/journal.pone.0008157.

3. Stanley PJ, Wilson R, Greenstone MA, MacWilliam L, Cole PJ. Effect of cigarette smoking on nasal mucociliary clearance and ciliary beat frequency. Thorax. 1986;41(7):519-23, http://dx.doi.org/10.1136/thx.41.7.519.

4. Karaman M, Tek A. Deleterious effect of smoking and nasal septal deviation on mucociliary clearance and improvement after septoplasty. Am J Rhinol Allergy. 2009;23(1):2-7, http://dx.doi.org/10.2500/aja.2009.23.3253.

5. Nakagawa NK, Franchini ML, Driusso P, Oliveira LR, Saldiva PHN, et al. Effects of a heat and moisture exchanger and a heated humidifier on nasal mucociliary clearance and ciliary beat frequency. Chest. 2005;128(4):2772-77, http://dx.doi.org/10.1136/chest.128.4.2772.

6. Astrand ABM, Hemmerling M, Root J, Wingren C, Pesic J, Johansson E, Wilczynski K, Blomqvist C. The effect of cigarette smoking on nasal mucociliary clearance and ciliary beat frequency. Chest. 2002;121(5):1561-66, http://dx.doi.org/10.1378/chest.121.5.1561.

7. Nicola ML, Carvalho HB, Yoshida CT, Anjos F, Nakao M, Santos UP, et al. Young “healthy” smokers have functional and inflammatory changes in the nasal and lower airways. Chest. 2014;145(5):998-1005, http://dx.doi.org/10.1378/chest.13-1355.

8. Pagliuca G, Rosato C, Marteluzzi S, de Vincentinis M, Greco A, Fusconi M, et al. Cytologic and functional alterations of nasal mucosa in smokers: a temporary or permanent damage? Otolaryngol Head Neck Surg. 2015;152(4):740-5, http://dx.doi.org/10.1177/019459981565998.

9. Cosio MG, Exnerova D, Niewoehner DE. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis. 1986;122(2):265-271, http://dx.doi.org/10.1183/0300241.86.122.265.

10. Konrad F, Schreiber T, Brecht-Kraus D, Georgieff M, Niewoehner DE. Increased alveolar epithelial permeability in cigarette smokers. Lancet. 1980;1(8159):68-9, http://dx.doi.org/10.1016/S0140-6736(80)90493-6.

11. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD: Assessment and impact. BTS Airways Guidelines. 2007;5(Suppl 3):1-34, http://dx.doi.org/10.1183/13993003,5.3-S3.1.

12. Meyer KC. Lung infections and aging. Ageing Res Rev. 2004;3:55-67, http://dx.doi.org/10.1016/S1568-9565(03)00007-7.

13. Dreyse J, Diaz O, Repetto PB, Morales A, Saldías F, Lisboa C. Do frequent nasal infections contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers? Intern J COPD. 2015;10:525-33, http://dx.doi.org/10.2147/COPD.S64745.

14. Decramer M, Nici L, Nardini S, Reardon J, Rohester CL, Sanguinetti CM, et al. Targeting the COPD exacerbation. Respir Med. 2008;102(1):53-15, http://dx.doi.org/10.1016/j.resmed.2007.08.023.

15. Celi BR. Update on the management of COPD. Chest. 2008;133:1451-62, http://dx.doi.org/10.1378/chest.07-0261.

16. Doll R, Petro R, Bondhur J. Mortality in smoking: A review of smoking mortality in male British doctors. Br Med J 1940;2:398, http://dx.doi.org/10.1136/bmj.2.3412.5549.AE.

17. Anthonisen NR, Sears MA, Wise RA, Manfreda J, Kaner RE, Connell JE. The effects of a smoking cessation intervention on 14-year mortality: a randomized clinical trial. Am Intern Med. 2005;142(1):2-3, http://dx.doi.org/10.1001/archinte.142.1.3.

18. Saldiva PHN, et al. Effects of a heat and moisture exchanger and a heated humidifier on nasal mucociliary clearance and ciliary beat frequency. Chest. 2005;128(4):2772-77, http://dx.doi.org/10.1136/chest.128.4.2772.

19. Oliveira-Maul JP, Carvalho HB, Goto DM, Maia RM, Flo C, Barnabe V, et al. Aging, diabetes and hypertension are associated with decreased nasal mucociliary clearance. Chest. 2013;143(4):1091-97, http://dx.doi.org/10.1378/chest.12-1183.

20. King M, Brock G, Lundell C. Clearance of mucus by simulated cough. Am J Physiol Lung Cell Mol Physiol. 2009;297(5):L1111-L1118, http://dx.doi.org/10.1152/ajplung.90391.2008.

21. Nakagawa NK, Macchiore M, Petrolino HM, Guimaraes ET, King M, Saldiva PHN, et al. Effects of a heat and moisture exchanger and a heated humidifier on respiratory mucous in patients undergoing mechanical ventilation. Crit Care Med. 2000;28(2):312-7, http://dx.doi.org/10.1097/00003156-200002000-00004.

22. Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson NF Jr, Meyer DA, Norman PS, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis. 1986;134(6):397-402.